Literature DB >> 12234786

Acute and chronic NOS inhibition enhances alpha(2)- adrenoreceptor-stimulated RhoA and Rho kinase in rat aorta.

Rebecca W Carter1, McKenzie Begaye, Nancy L Kanagy.   

Abstract

We demonstrated that arteries from rats made hypertensive with chronic nitric oxide (NO) synthase (NOS) inhibition (N(omega)-nitro-L-arginine in drinking water, LHR) have enhanced contractile sensitivity to alpha(2)-adrenergic receptors (alpha(2)-AR) agonist UK-14304 compared with arteries from normotensive rats (NR). NO may regulate vascular tone in part through suppression of RhoA and Rho kinase (ROK). We hypothesized that enhanced RhoA and ROK activity augments alpha(2)-AR contraction in LHR aortic rings. Y-27632 eliminated UK-14304 contraction in LHR and NR aortic rings. The order of increasing sensitivity to Y-27632 was the following: endothelium-intact NR, LHR, and endothelium-denuded NR. UK-14304 stimulated RhoA translocation to the membrane fraction in LHR and denuded NR but not in intact NR aorta. Basally, more RhoA was present in the membrane fraction in denuded NR than in intact NR or LHR aorta. Relaxation to S-nitroso-N-acetyl-penicillamine and Y-27632 in denuded ionomycin-permeabilized rings was greater in NR than in LHR. Together these studies indicate alpha(2)-AR contraction depends on ROK activity more in NR than LHR aorta. Additionally, endogenous NO may regulate RhoA activation, whereas chronic NOS inhibition appears to cause RhoA desensitization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234786     DOI: 10.1152/ajpheart.01101.2001

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  14 in total

1.  Exhaustive swimming differentially inhibits P2X1 receptor- and α1-adrenoceptor-mediated vasoconstriction in isolated rat arteries.

Authors:  Lu Li; Tao Wu; Cong Wei; Jian-ke Han; Zhen-hua Jia; Yi-ling Wu; Lei-ming Ren
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

2.  Rho kinase inhibitors reduce neurally evoked contraction of the rat tail artery in vitro.

Authors:  Melanie Yeoh; James A Brock
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

3.  {alpha}-Adrenoceptor constrictor responses and their modulation in slow-twitch and fast-twitch mouse skeletal muscle.

Authors:  David G Lambert; Gail D Thomas
Journal:  J Physiol       Date:  2004-12-23       Impact factor: 5.182

Review 4.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

5.  Effects of pregnancy, hypertension and nitric oxide inhibition on rat uterine artery myogenic reactivity.

Authors:  Carolyn Barron; Maurizio Mandala; George Osol
Journal:  J Vasc Res       Date:  2010-04-30       Impact factor: 1.934

Review 6.  Understanding and targeting the Rho kinase pathway in erectile dysfunction.

Authors:  Nikolai A Sopko; Johanna L Hannan; Trinity J Bivalacqua
Journal:  Nat Rev Urol       Date:  2014-10-14       Impact factor: 14.432

Review 7.  The pericyte: cellular regulator of microvascular blood flow.

Authors:  Matthew E Kutcher; Ira M Herman
Journal:  Microvasc Res       Date:  2009-02-07       Impact factor: 3.514

8.  Inhibition of nitric oxide synthases abrogates pregnancy-induced uterine vascular expansive remodeling.

Authors:  George Osol; Carolyn Barron; Natalia Gokina; Maurizio Mandala
Journal:  J Vasc Res       Date:  2009-02-10       Impact factor: 1.934

9.  Role of alpha2C-adrenoceptors in the reduction of skin blood flow induced by local cooling in mice.

Authors:  M Honda; M Suzuki; K Nakayama; T Ishikawa
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

10.  Tyramine Reveals Failing α2-Adrenoceptor Control of Catecholamine Release and Total Peripheral Vascular Resistance in Hypertensive Rats.

Authors:  Torill Berg; Jørgen Jensen
Journal:  Front Neurol       Date:  2013-02-28       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.